Non Hodgkin Lymphoma Clinical Trial

Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas

Summary

To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Patients must have the following:

Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria.
Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease.
Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.
Signed written informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
Stage IE Central Nervous System lymphomas.

Patients with the following are excluded:

More than one previous treatment for lymphoma.
Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
Conditions that preclude obtaining an informed consent.
Not accessible for scheduled treatment visits or follow-up.
Stage IE Central Nervous System (CNS) lymphomas.

Prior Medication:

Excluded within 2 weeks of study entry:

Zidovudine.
Excluded:
Doxorubicin dosing = or > 300 mg/m2.

Prior Treatment:

Excluded:

Received more than one previous treatment regimen for lymphoma.

Required:

Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Study ID:

NCT00002003

Recruitment Status:

Completed

Sponsor:

Lederle Laboratories

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

UMDNJ - New Jersy Med School
Newark New Jersey, 07103, United States
New York Univ Med Ctr
New York New York, 10016, United States
Saint Luke's - Roosevelt Hosp Ctr
New York New York, 10019, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Study ID:

NCT00002003

Recruitment Status:

Completed

Sponsor:


Lederle Laboratories

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider